These medical and medical enterprises, may go to science and technology board!

the original title: "Pharmaceutical melt" these medical and medical enterprises, may go to science and technology board!March 1, 2019, Order No153, "Science and Technology Board initial public offering of shareregistration management measures (trial)", "Order No154" "Science and Technology board listed companies continued supervision measures (trial)" officially issuedThe following is pharmaceutical data, Pharnex Datamonitor speculates, for the medical industry practitioners, investors for reference1 Kozi Biology11 CAR-T cell therapy products, including GPC3, CD19, BCMA, CLAUDIN18.2, EGFR/EGFRVIII, etc., are currently under development and have received 3 NMPA clinical approvalsmost notable is the treatment of GPC3-positive solid tumors, pending the late preliminary research disclosure2 Zeai Bio
Zeai's new drug pipeline covers three disease areas, malignant tumors, blood diseases and surgical hemostaticAccording to the drug's melting data, Pharnex Datamonitor speculates that the zeitgeist bio-thorium is probably:Donafini Solafini (Bayer);Jacktini: JAK inhibitor Momelotinib (Gilead);ZG0320: ALK inhibitor Ceritinib (Novartis);ZG0128: Ialdelisib (Gilead)3 Science and The Virtue
REMD-477 is a sugar-reducing antibody drug for G-protein conjugate receptorsThe image below is Remetpipelinehttp://
4 Kangfang Bio
1.1Kangfang Pharmaceutical Co., Ltd.'s new anti-PD-1/CTLA-4 dual-specific antibody drug AK104 launched phase Ib/II clinical trials in China in March 2019AK104 is kangfang bio-utilization Tetrabody dual-resistance platform, independent research and development of the first dual-resistance products2It is worth noting that AK107, authorized by Mercadon, is still not clinical, according to pharmacomes data500 Otay Biological1On August 17, 2018, the listing application for Baiote Adamu mono-anti-injection was accepted by CDE, the first reported adamu mono-anti-biosimilar drug in China2.BAT1806 (Tozhu monoantigen) Global Phase III clinical study has completed the first patient administrationAnd so on
6 Junshi biologicalJunshi biological in the future of the new three boards in the country will not rule out the withdrawal of the market, landing science and technology board 1 Junshi Bio, Tuyi, Triprei monoantigen injection, currently approved forindications is melanoma 240mg / branch, 7200 yuan, annual cost of 1872 million yuan, has been sold nationwide 2 Junshi's Pipeline, the nervous system disease CNS, the drug melt data speculated that JS010 is a migraine antibody drug, CGRP receptor antagonists Currently, the FDA has three antibodies on the market, all last year May 2018, Amgen and Novartis Erenumab-aooe, the world's first targeted CGRP receptor antagonist and the first new drug to prevent migraines in the U.S market in nearly 20 years ; 7 Shenzhou Cells
1 At present, the company's product line has EGFR/CD20/HER2 monoantigen; 2 In the past year, Stone Pharmaceutical Group (01093) entered into an agreement with Shenzhou Cell Engineering Co., Ltd on the authorization and commercialization of anti-CD20 monoclonal antibodies (SCT400) for injection with the development of Shenzhou Cell Engineering The product is conducting Phase III clinical trials in China on non-Hodgkin's lymphoma indications and is expected to submit a biologics license application in the first quarter of 2019 as the exclusive license, Shipharma paid up to 650 million yuan in pre-stage and development milestone payments to Shenzhou Cell Engineering based on the approval progress of the product in the region 8 micro-core biological potential pharmaceutical stock: micro-core biological has received guidance on the listing! 9
other biopharmaceutical companies that may land on the science and technology board have speculated that there are Fuhong Hanxuan, Sea and Biology, Jiahe Bio, Paige Bio, etc 10 medical-related other enterprises
such as Dr Chunyu, Co-effects, World and Genes also do not rule out preparations New Year's blockbuster: 100 Of the domestic Biotech product lines (I) references: Pharmaceutical Melt data, Pharnex Datamonitor; Pharmaceutical melting companies publicly disclosed;